---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-025820"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:00:27.701875+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BiomX Announces Positive Phase 2 Results for BX211 in Diabetic Foot Osteomyelitis

## Summary
- BX211 showed statistically significant ulcer size reduction (PAR) at week 12 (p=0.046) and week 13 (p=0.052) vs placebo.
- BX211 reduced ulcer depth (p=0.048) and limited ulcer area expansion (p=0.017) compared to placebo.
- Phase 2 trial enrolled 41 patients (26 BX211, 15 placebo) with DFO associated with S. aureus; BX211 safe and well-tolerated.
- BiomX plans Phase 2/3 trial pending FDA feedback; KOL event scheduled April 3, 2025.

## SEC filing metadata
- accession: 0001213900-25-025820
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390025025820/0001213900-25-025820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390025025820/ea0236313-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-025820
- JSON: https://secwatch.observer/filing/0001213900-25-025820.json
- Plain text: https://secwatch.observer/filing/0001213900-25-025820.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.